CYP19A1 and Pruritus: ET encompasses aromatase inhibitors (AI) and selective estrogen receptor modulators (SERM), and the most commonly reported cAEs include pruritus, alopecia, a clinically heterogeneous cutaneous rash, skin flushing, vulvovaginal atrophy, and connective tissue disorders [27,28,29].